Vaccinex Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Vaccinex Inc in the fourth quarter 2024?
Due to the lack of equity, it was not possible to calculate Vaccinex Inc 's return on equity (ROE) in its fourth quarter 2024

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter
Y / Y Equity Change	-	-	-	10.62 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-19	-19	-18	-19	-20
Return On Equity (TTM)	-	-	-	-	-
VCNX's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	-2	-1	-3	3	-2
Seq. Equity Change	-	-	-	-	-
Seq. Net Income Change	-	-	-	-	-

Back to VCNX Management Effectiveness >> VCNX's 5 Years Annual ROE >> Compare VCNX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

News about Vaccinex Inc Return on Equity ROE

Vaccinex Inc. Showcases Strategic Advancements in Alzheimers Disease Research and Financial Performance

Vaccinex Inc., a biotechnology company dedicated to developing therapeutics for neurological diseases, has made significant strides in its clinical and financial arenas. Recently, the company provided updates on the SIGNAL-AD Phase 1b/2 trial of its investigational therapy, Pepinemab, in Alzheimer s disease, while also reporting impressive financial metrics in its third quarter of 2023. This article seeks to synthesize findings from these developments, providing a overview of Vaccinex’s goals, trial significance, and financial achievements, along with a glimpse into its future potential. Trial Update: SIGNAL-AD Phase 1b/2 Vaccinex s SIGNAL-AD trial is pivotal in assessing the safety, tolerability, and efficacy of Pepinemab, a monoclonal antibody designed to target the semaphorin-4D (sema4D), a molecule implicated in neurodegeneration in Alzheimer’s disease. The recent update emphasizes the trial s goals and significance, where Vaccinex aims to elucidate Pepinemab s potential to decelerate cognitive decline in patients with this debilitating condition. The company anticipates that positive outcomes from the trial will support further clinical development and facilitate partnership opportunities with larger pharmaceutical entities. The pursuit of partnerships is a strategic move that could amplify the resources and expertise needed to advance their research and ensure that Pepinemab reaches the market promptly if proven effective.

Vaccinex Granted Nasdaq Extension Amidst Strong Q3 2023 Performance, Boosting Investor Confidence

In a recent development, Vaccinex Inc, the renowned biotechnology company, has been granted an extension until March 4, 2024, by the Nasdaq stock exchange to regain compliance with its listing rule. The listing rule in question pertains to the minimum bid price requirement. Vaccinex has reassured Nasdaq that it is taking necessary measures to meet this requirement, instilling confidence among investors and stakeholders.
The extension comes as a relief for Vaccinex, providing them with ample time to rectify any compliance-related issues and ensure a seamless continuation of their trading on the Nasdaq platform. By granting an extension, Nasdaq has demonstrated its willingness to support the company in returning to compliance, reflecting their faith in Vaccinex s potential.

VCNX Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Equity in Millions	-2	-2	5	7	-3
Y / Y Equity Change	-	-	-29.94 %	-	-
Net Income in Millions	-19	-20	0	-22	-29
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-	-	0 %	-301.94 %	-

Back to VCNX Management Effectiveness >> VCNX's 5 Years Annual ROE >> Compare VCNX ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VCNX's' Return on Equity at Yahoo Finance
VCNX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VCNX's Competitors
Subscribers only: Roe for Vaccinex Inc 's Suppliers
Subscribers only: Return On Equity for VCNX's Customers

Companies with similar Return On Equity at Dec 31 2024, within Healthcare Sector	ROE
Inhibrx Biosciences Inc	1,243.18 %
Hca Healthcare Inc	674.13 %
Gridai Technologies Corp	597.06 %
Polypid Ltd	377.69 %

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.